Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. The study focuses on using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study”
Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio”
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://nnw.fm/YBH97). “Yale researchers found that … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin”
Cybin names Dr. Amir Inamdar as chief medical officer for European operations The company appoints Dr. Geoff Varty as head of research and development Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as “Year 2 Q1 (i)-(iii).” According to the update, the milestones were contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Achievement of Adelia Milestones”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the new head of research & development. In addition, the company has made some … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members”
WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19 People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection Cybin is on a mission to revolutionize mental healthcare A World Health Organization (“WHO”) survey covering 130 … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two upcoming investor conferences. The company announced that CEO Doug Drysdale will be presenting virtually in a fireside chat during the Cantor Virtual Global Healthcare Conference and, during the Benzinga Healthcare Small Cap Conference, Drysdale will be presenting … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present in Two Upcoming Investor Conferences”
